Antibodies News and Research

RSS

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Researchers demonstrated the inhalation of an ACE2 decoy receptor, sACE22.v2.4-IgG1, increases survival and ameliorates lung injury in K18-hACE2 transgenic mice.

30 Mar 2022

Antiviral functions of interferon regulatory factors during human coronavirus infection

Researchers assessed the roles of the interferon regulatory factors: IRF1, IRF3, and IRF7 in infections by human coronaviruses.

30 Mar 2022

Divalent SARS-CoV-2 fusion vaccine found to be effective in mice

Researchers bioengineered a divalent fusion vaccine by combining the immunogenic region of the nucleocapsid protein and the receptor-binding domain of the spike protein of SARS-CoV-2.

30 Mar 2022

Study describes the identification of a SARS-CoV-2 variant that escapes detection by antigen tests

Researchers raised concerns that some SARS-CoV-2 variants can escape detection by antigen tests.

30 Mar 2022

Preclinical investigation of intranasal adjuvanted COVID-19 vaccine

A new study reported systemic and mucosal immunity against SARS-CoV-2 via intranasal delivery of a vaccine containing recombinant SARS-CoV-2 antigens, nucleocapsid, and spike subunit.

30 Mar 2022

ProteoGenix launches new XtenCHOTM Transient CHO Expression System to improve biologics development

ProteoGenix, a contract research organization specialized in biologics discovery and bioproduction, announces the launch of its XtenCHOTM Transient Expression System.

From ProteoGenix 30 Mar 2022

Engineering rotavirus-based vaccine vectors expressing SARS-CoV-2 spike epitopes

Researchers proposed rotavirus-based vaccine vectors with the potential for developing polyvalent vaccines targeting multiple enteric viruses, including SARS-CoV-2.

30 Mar 2022

The potential efficacy of nasal nanoparticle COVID-19 vaccines

The current paper reviews progress in this field regarding nasal nanoparticle vaccines for COVID-19.

30 Mar 2022

A ferritin nanoparticle candidate vaccine for COVID

In a recent study published on the bioRxiv* preprint server, the immunogenicity, and effectiveness of SARS-CoV-2 spike ferritin nanoparticle (SpFN) adjuvanted with aluminum hydroxide (AlOH3) or Army Liposomal Formulation QS-21 (ALFQ) in a cynomolgus macaque (CM) COVID-19 model was evaluated.

30 Mar 2022

Immunity against SARS-CoV-2 BA.1, BA.2, and BA.3 after three doses of BNT162b2 vaccine

A new study assesses the neutralization of three Omicron sublineages by BNT162b2-vaccinated sera collected one month after the third vaccine dose. A preprint version of the study is available on the bioRxiv* server while the article undergoes peer review.

29 Mar 2022

Study finds less diverse circulating antibodies in aging killifish

As we age, our immune system works less well. We become more susceptible to infections and vaccinations no longer work as effectively.

29 Mar 2022

Viewpoint explains how T cell testing can help research on population-level SARS-CoV-2 adaptive immunity and inform public health policies

A recent viewpoint illustrated that evaluating T cell responses to COVID-19 is essential to inform public health initiatives.

29 Mar 2022

Evaluating serological responses to repeated COVID-19 vaccination in kidney transplant recipients

Researchers analyzed whether repeated vaccinations against COVID-19 increase serological response in non-responding kidney transplant recipients.

29 Mar 2022

Immune response dynamics following COVID-19 heterologous and homologous vaccinations

Researchers evaluated the cellular and humoral immunity following heterologous and homologous COVID-19 immunization regimens for up to five months.

29 Mar 2022

Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice

In a new study, researchers tested the bi-, tri-, and tetravalent formulations of Newcastle disease virus (NDV)-based low-cost vaccine in mice.

29 Mar 2022

Results of Phase 3 Nanocovax SARS-CoV-2 vaccine trial suggest robust effectiveness

A new study presented the findings of the Phase 3 trial of the Nanocovax coronavirus disease 2019 (COVID-19) vaccine.

29 Mar 2022

Is SARS-CoV-2 a Superantigen?

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), scientists have been conducting extensive studies to understand various aspects of the virus. Researchers have stated that SARS-CoV-2 manifests several biological and clinical consequences of a superantigen

29 Mar 2022

One year after severe COVID-19, T cells persist against SARS-CoV-2

In a recently published article in the journal eBioMedicine, scientists have demonstrated that critically ill coronavirus disease 2019 (COVID-19) patients are capable of generating durable memory T cell response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for more than one year after hospital discharge.

28 Mar 2022

Northwestern scientists continue to advance the understanding of COVID-19

As the COVID-19 pandemic enters its third year, Northwestern Medicine scientists continue to help advance the understanding of the disease and its impact, from investigating antibody protection against COVID-19 reinfection to elevating women in academic research and highlighting racial and ethnic disparities in COVID-19 hospital mortality in Illinois.

28 Mar 2022

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly

Researchers determine whether there was any reduction in the death rate in elderly COVID-19 patients following the second booster dose.

28 Mar 2022

Antibodies News and Research

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Antiviral functions of interferon regulatory factors during human coronavirus infection

Divalent SARS-CoV-2 fusion vaccine found to be effective in mice

Study describes the identification of a SARS-CoV-2 variant that escapes detection by antigen tests

Preclinical investigation of intranasal adjuvanted COVID-19 vaccine

ProteoGenix launches new XtenCHOTM Transient CHO Expression System to improve biologics development

Engineering rotavirus-based vaccine vectors expressing SARS-CoV-2 spike epitopes

The potential efficacy of nasal nanoparticle COVID-19 vaccines

A ferritin nanoparticle candidate vaccine for COVID

Immunity against SARS-CoV-2 BA.1, BA.2, and BA.3 after three doses of BNT162b2 vaccine

Study finds less diverse circulating antibodies in aging killifish

Viewpoint explains how T cell testing can help research on population-level SARS-CoV-2 adaptive immunity and inform public health policies

Evaluating serological responses to repeated COVID-19 vaccination in kidney transplant recipients

Immune response dynamics following COVID-19 heterologous and homologous vaccinations

Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice

Results of Phase 3 Nanocovax SARS-CoV-2 vaccine trial suggest robust effectiveness

Is SARS-CoV-2 a Superantigen?

One year after severe COVID-19, T cells persist against SARS-CoV-2

Northwestern scientists continue to advance the understanding of COVID-19

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly

Antibodies eBook

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Automating research - solutions and best practices

Latest Life Science News